Azacitidine Accord 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification1 
Decision 
Information 
issued on 
Issued2 / 
affected3  
amended 
on 
IAIN/0018 
C.I.z - Changes (Safety/Efficacy) of Human and 
04/01/2024 
SmPC and PL 
Veterinary Medicinal Products - Other variation 
IA/0017 
A.5.b - Administrative change - Change in the name 
15/06/2023 
n/a 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
(excluding manufacturer for batch release) 
IB/0014/G 
This was an application for a group of variations. 
02/03/2023 
n/a 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.II.b.3.a - Change in the manufacturing process of 
the finished or intermediate product - Minor change 
in the manufacturing process 
B.II.b.1.f - Replacement or addition of a 
manufacturing site for part or all of the 
manufacturing process of the FP - Site where any 
manufacturing operation(s) take place, except batch 
release, batch control, and secondary packaging, for 
sterile medicinal products (including those that are 
aseptically manufactured) excluding biological/ 
immunological medicinal products 
IA/0016 
A.5.b - Administrative change - Change in the name 
14/02/2023 
n/a 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
IB/0015 
C.I.2.a - Change in the SPC, Labelling or PL of a 
25/01/2023 
15/03/2023 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
Page 2/5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0012/G 
This was an application for a group of variations. 
17/08/2022 
n/a 
B.II.b.3.a - Change in the manufacturing process of 
the finished or intermediate product - Minor change 
in the manufacturing process 
B.II.b.4.z - Change in the batch size (including batch 
size ranges) of the finished product - Other variation 
IB/0011 
C.I.2.a - Change in the SPC, Labelling or PL of a 
19/07/2022 
15/03/2023 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
II/0009 
B.II.e.5.c - Change in pack size of the finished 
17/02/2022 
29/04/2022 
SmPC, 
product - Change in the fill weight/fill volume of 
sterile multidose (or single-dose, partial use) 
parenteral medicinal products, including 
biological/immunological medicinal products 
Labelling and 
PL 
IA/0010 
A.7 - Administrative change - Deletion of 
24/01/2022 
29/04/2022 
Annex II and 
manufacturing sites 
PL 
IB/0008 
B.II.d.1.z - Change in the specification parameters 
03/11/2021 
n/a 
and/or limits of the finished product - Other variation 
IB/0007/G 
This was an application for a group of variations. 
05/07/2021 
29/04/2022 
SmPC and PL 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
Page 3/5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IB/0005/G 
This was an application for a group of variations. 
25/05/2021 
n/a 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
B.I.d.1.a.4 - Stability of AS - Change in the re-test 
period/storage period - Extension or introduction of a 
re-test period/storage period supported by real time 
data 
B.I.b.1.c - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Addition of a new 
specification parameter to the specification with its 
corresponding test method 
B.I.a.4.c - Change to in-process tests or limits 
applied during the manufacture of the AS - Deletion 
of a non-significant in-process test 
A.7 - Administrative change - Deletion of 
Page 4/5 
 
 
 
 
 
 
 
 
 
manufacturing sites 
IAIN/0006 
B.II.b.1.a - Replacement or addition of a 
30/04/2021 
n/a 
manufacturing site for the FP - Secondary packaging 
site 
IAIN/0004 
B.II.b.2.c.1 - Change to importer, batch release 
23/03/2021 
29/04/2022 
Annex II and 
arrangements and quality control testing of the FP - 
PL 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
IA/0003 
B.I.a.3.a - Change in batch size (including batch size 
06/11/2020 
n/a 
ranges) of AS or intermediate - Up to 10-fold 
increase compared to the originally approved batch 
size 
IB/0002 
B.II.b.4.z - Change in the batch size (including batch 
09/09/2020 
n/a 
size ranges) of the finished product - Other variation 
IB/0001 
B.II.d.1.z - Change in the specification parameters 
18/03/2020 
n/a 
and/or limits of the finished product - Other variation 
Page 5/5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
